A strategy for the engineering of insulin producing cells with a broad spectrum of defense properties

Biomaterials

Volumn 32, Issue 7, 2011, Pages 1816-1825

  Bloch, Konstantin ^a   Bloch, Olga ^a   Tarasenko, Igor ^a   Lazard, Daniel ^a   Rapoport, Micha ^a   Vardi, Pnina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alginate encapsulation; Cell therapy; Diabetes; Insulinoma; Xenotransplantation

Indexed keywords

ALGINATE ENCAPSULATION; CELL THERAPY; DIABETES; INSULINOMA; XENOTRANSPLANTATION;

ALGINATE; CYTOLOGY; GLUCOSE; HYDROGEN PEROXIDE; INSULIN; NITRIC OXIDE;

CELLS;

ALGINIC ACID; INSULIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL SURVIVAL; ENCAPSULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALGINATES; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCURONIC ACID; HEXURONIC ACIDS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TISSUE THERAPY;

MUS; RATTUS;

EID: 78650995342     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.11.018     Document Type: Article

References (33)

1. Tiedge M., Lortz S., Munday R., Lenzen S. Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia 1999, 42:849-855.
2. Lortz S., Tiedge M., Nachtwey T., Karlsen A.E., Nerup J., Lenzen S. Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes. Diabetes 2000, 49:1123-1130.
3. Dionne K.E., Colton C.K., Yarmush M.L. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993, 42:12-21.
4. Papas K.K., Suszynski T.M., Colton C.K. Islet assessment for transplantation. Curr Opin Organ Transplant 2009, 14:674-682.
5. Lau J., Henriksnäs J., Svensson J., Carlsson P.O. Oxygenation of islets and its role in transplantation. Curr Opin Organ Transplant 2009, 14:688-693.
6. McCabe C., Samali A., O'Brien T. Cytoprotection of beta cells: rational gene transfer strategies. Diabetes Metab Res Rev 2006, 22:241-252.
7. Vériter S., Mergen J., Goebbels R.M., Aouassar N., Grégoire C., Jordan B., et al. In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A 2010, 16:1503-1513.
8. Lau J., Kampf C., Mattsson G., Nyqvist D., Köhler M., Berggren P.O., et al. Beneficial role of pancreatic microenvironment for angiogenesis in transplanted pancreatic islets. Cell Transplant 2009, 18:23-30.
9. Bloch K., Vanichkin A., Damshkaln L.G., Lozinsky V.I., Vardi P. Vascularization of wide-porous agarose-gelatin cryogel scaffolds implanted subcutaneously in diabetic and non diabetic mice. Acta Biomater 2010, 6:1200-1205.
10. Wu H., Avgoustiniatos E.S., Swette L., Bonner-Weir S., Weir G.C., Colton C.K. In situ electrochemical oxygen generation with an immunoisolation device. Ann N Y Acad Sci 1999, 875:105-125.
11. Bloch K., Papismedov E., Yavriyants K., Vorobeychik M., Beer S., Vardi P. Photosynthetic oxygen generator for bio-artificial pancreas. Tissue Eng 2006, 12:337-344.
12. Newgard C.B. Cellular engineering and gene therapy strategies for insulin replacement in diabetes. Diabetes 1994, 43:341-350.
13. Pileggi A., Fenjves E.S., Klein D., Ricordi C., Pastori R.L. Protecting pancreatic beta-cells. IUBMB Life 2004, 56:387-394.
14. Bloch K.O., Zemel R., Bloch O.V., Grief H., Vardi P. Streptozotocin and alloxan-based selection improves toxin resistance of insulin-producing RINm cells. Int J Exp Diabetes Res 2000, 1:211-219.
15. Bloch K., Vardi P. Therapeutic differentiation of tumor-derived insulin-producing cells selected for resistance to diabetogenic drugs. Int J Exp Diabetes Res 2000, 1:233-237.
16. Liu H.K., McCluskey J.T., McClenghan N.H., Flatt P.R. Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity. Endocrine 2007, 32:20-29.
17. Liu H.K., McCluskey J.T., McClenghan N.H., Flatt P.R. Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enables selection of robust toxin-resistant cells but with decreased gene expression of insulin secretory function. Pancreas 2008, 36:294-301.
18. Bloch K., Voribeychyk M., Yavriyants K., Vardi P. Selection of insulin-producing RIN cells with improved resistance to oxidative stress. Biochem Pharmacol 2003, 65:1797-1805.
19. Chen G., Hohmeier H.E., Gasa R., Tran V.V., Newgard C.B. Selection of insulinoma cell lines with resistance to interleukin-1beta- and gamma-interferon-induced cytotoxicity. Diabetes 2000, 49:562-570.
20. Tran V.V., Chen G., Newgard C.B., Hohmeier H.E. Discrete and complementary mechanisms of protection of beta-cells against cytokine-induced and oxidative damage achieved by bcl-2 overexpression and a cytokine selection strategy. Diabetes 2003, 52:1423-1432.
21. Bloch K., Vardi P. Toxin-based selection of insulin-producing cells with improved defense properties for islet cell transplantation. Diabetes Metab Res Rev 2005, 21:253-261.
22. Hohmeier H.E., Tran V.V., Chen G., Gasa R., Newgard C.B. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int J Obes Relat Metab Disord 2003, Suppl. 3:S12-S16.
23. Maguire T., Novik E., Schloss R., Yarmush M. Alginate-PLL microencapsulation: effect on the differentiation of embryonic stem cells into hepatocytes. Biotechnol Bioeng 2006, 93:581-591.
24. Halban P.A., German M.S., Kahn S.E., Weir G.C. Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 2010, 95:1034-1043.
25. de Vos P., Faas M.M., Strand B., Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006, 27:5603-5617.
26. King A., Andersson A., Sandler S. Cytokine-induced functional suppression of microencapsulated rat pancreatic islets in vitro. Transplantation 2000, 70:380-383.
27. Basta G., Sarchielli P., Luca G., Racanicchi L., Nastruzzi C., Guido L., et al. Optimized parameters for microencapsulation of pancreatic islet cells: an in vitro study clueing on islet graft immunoprotection in type 1 diabetes mellitus. Transpl Immunol 2004, 13:289-296.
28. Merani S., Toso C., Emamaullee J., Shapiro A.M. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008, 95:1449-1461.
29. Hohmeier H., Newgard C. Cell lines derived from pancreatic islets. Molecular and Cellular Endocrinology 2004, 228:121-128.
30. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
31. Rothe H., Kolb H. Strategies of protection from nitric oxide toxicity in islet inflammation. J Mol Med 1999, 77:40-44.
32. Ko S.H., Ryu G.R., Kim S., Ahn Y.B., Yoon K.H., Kaneto H., et al. Inducible nitric oxide synthase-nitric oxide plays an important role in acute and severe hypoxic injury to pancreatic beta cells. Transplantation 2008, 85:323-330.
33. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997, 46:1733-1742.